Human Anti-HIV-1 Env Recombinant Antibody (clone CAP228-3D) (CAT#: PABC-420)

This product is a recombinant Human antibody that can recognize HIV-1 env.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 CAP228 antibodies efficiently inhibit α4β7 integrin binding.

Figure 1 CAP228 antibodies efficiently inhibit α4β7 integrin binding.

Inhibition of ConC gp120 binding to α4β7 integrin transfected 293 T cells by V2p mAbs CAP228-16H (green), CAP228-3D (orange) or CH58 (blue). Percentage blocking (y-axis) was calculated from the difference in mean fluorescence intensity (MFI) when cell-gp120 complexes were made in the presence or absence of antibody. The α4β7 specific antibodies HP21 (purple) and ACT1 (red) were used as positive controls, while an irrelevant RSV antibody (palivizumab) and an HIV-1 CD4 binding site-specific antibody (VRC01) were used as the negative controls.

Wibmer, C. K., Richardson, S. I., Yolitz, J., Cicala, C., Arthos, J., Moore, P. L., & Morris, L. (2018). Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions. Nature communications, 9(1), 4489.

ELISA

Figure 2 Endpoint ELISA binding titres of V2p mAbs CAP228-16H (green), CAP228-3D (orange) or CH59 (light blue), quaternary structure dependent V2q mAb PGT145 (purple) or V2i mAb 830 A (yellow) to concentrated pseudovirus expressing the C1080 envelope.

Figure 2 Endpoint ELISA binding titres of V2p mAbs CAP228-16H (green), CAP228-3D (orange) or CH59 (light blue), quaternary structure dependent V2q mAb PGT145 (purple) or V2i mAb 830 A (yellow) to concentrated pseudovirus expressing the C1080 envelope.

HIV-1 CD4 binding site-specific antibody VRC01, and an irrelevant Flu-specific antibody were used as positive or negative controls, respectively.

Wibmer, C. K., Richardson, S. I., Yolitz, J., Cicala, C., Arthos, J., Moore, P. L., & Morris, L. (2018). Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions. Nature communications, 9(1), 4489.

ELISA

Figure 3 ELISA showing binding to the autologous transmitted/founder CAP228 V1V2 scaffolded protein by wild-type CAP228-16H (green), and the ED-motif mutant (red), when compared to antibodies that naturally contain the ED motif: CAP228-3D (purple), CH58 (blue), and CH59 (gray).

Figure 3 ELISA showing binding to the autologous transmitted/founder CAP228 V1V2 scaffolded protein by wild-type CAP228-16H (green), and the ED-motif mutant (red), when compared to antibodies that naturally contain the ED motif: CAP228-3D (purple), CH58 (blue), and CH59 (gray).

Absorbance readings are plotted on the y axis versus mAb concentration on the x axis.

Van Eeden, C., Wibmer, C. K., Scheepers, C., Richardson, S. I., Nonyane, M., Lambson, B., . . . Morris, L. (2018). V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep, 25(11), 3123-3135 e3126.


Specifications

  • Host Species
  • Human
  • Type
  • Human IgG1
  • Specificity
  • HIV-1 env
  • Species Reactivity
  • HIV-1
  • Clone
  • CAP228-3D
  • Applications
  • ELISA, Inhib, Neut
  • Related Disease
  • HIV-1 Infection

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been tested for use in Enzyme-linked Immunosorbent Assay, Inhibition and Neutralization. It's recommended that the optimal antibody concentration, dilution, incubition time, etc. be carefully titrated in specific assays.

Target

  • Alternative Names
  • HIV-1 env; Human immunodeficiency virus type-1 envelope protein

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone CAP228-3D"

See other products for "HIV-1 Env"

Single-domain Antibody

CAT Product Name Application Type
NABG-057 Recombinant Anti-HIV-1 env VHH Single Domain Antibody ELISA, IHC, FC, FuncS Llama VHH

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABC-420. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare